Nkarta Inc (NAS:NKTX)
$ 2.87 -0.12 (-4.01%) Market Cap: 202.53 Mil Enterprise Value: 4.93 Mil PE Ratio: 0 PB Ratio: 0.47 GF Score: 38/100

Nkarta Inc at Barclays Global Healthcare Conference (Virtual) Transcript

Mar 11, 2021 / 03:20PM GMT
Release Date Price: $49 (+7.13%)
Peter Richard Lawson
Barclays Bank PLC, Research Division - Research Analyst

Great. Thank you so much. Good morning, everybody, and welcome to Barclays Global Healthcare Conference. My name is Peter Lawson. I'm one of the biotech equity analysts at Barclays. And thank you, everyone, for joining us today, taking time out of your day. Institutional investors, of course, can e-mail me for any questions. The address, it's [email protected]. And ping me on Bloomberg as well.

And it gives me great pleasure to introduce the management team from Nkarta. And with us today, we've got a whole roster, it seems, of the C-suite. So we've got Paul Hastings, CEO. Also have Ralph Brandenberg, the -- I'm just trying to remember your title again, Ralph. But I also got James Trager, Chief Scientific Officer. And we've got Kanya Rajangam, which I'm sorry I mispronounced your name, Chief Medical Officer. And I think that -- we've also, of course, got Greg Mann from IR. So thank you so much for joining us today.

And it's a story we don't cover at Barclays, but we find fascinating in cell therapy

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot